Salts of isobutyric acid (1 R*, 2R*, 4R*)-2-(2-{[3-(4,7-dimethoxy-1 H-benzoimidazol-2-yl)-methyl-amino}-ethyl)-5-phenyl-bicyclo[2.2.2]oct-5-en-2-yl ester

US8492555B2 · kind B2 · utility

Assignee

• Actelion Pharmaceuticals Ltd. · CH

Inventors

• Stefan Abele · Allschwil, CH
• Stéphanie Combes · Allschwil, CH
• Jacques-Alexis Funel · Allschwil, CH
• Kurt Hilpert · Therwil, CH
• Francis Hubler
• Katharina Reichenbaecher · Riehen, CH
• Dorte Renneberg · Allschwil, CH
• Markus Von Raumer · Allschwil, CH

Key dates

• Filing date: Oct 21, 2009
• Grant date: Jul 23, 2013
• Expiry date: Jan 5, 2030

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P9/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to crystalline salts of isobutyric acid (1R*,2R*,4R*)-2-(2-{[3-(4,7 -dimethoxy-1H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-5-phenyl-bicyclo[2.2.2]oct-5-en-2-yl ester, processes for the preparation thereof, pharmaceutical compositions containing said crystalline salts, and their use as medicaments, especially as calcium channel blockers.